intuitive surgical investor presentation 2021is it ok to give nexgard early
Icey Jiang - Google Women Techmakers Scholar - LinkedIn Jamie, anything? So it's hard to time it out, and it doesn't time out over one or two quarters, it times out over years. Investors have assigned a high trading . your options for e-mail notification, please enter your e-mail address below and click Gary S. Guthart Chief Executive Officer, Member of the Board of Directors. Even though we've seen growth in the procedures that were specifically targeted by extended use instruments, it's hard to discern what is COVID-related versus what is not. Presenter SpeechKari Krogstad Okay. Intuitive Surgical Is Falling After Earnings. This Analyst Thinks It's Intuitive Announces Fourth Quarter Earnings, www.intuitive.com/en-us/products-and-services/ion, Less: net income (loss) attributable to noncontrolling interest in joint venture. We're doing what we call the procedure development and the trial development around other indications, we think there'll be an opportunity in thoracic, as well as other ones beyond it. The compound annual revenue growth rate between the second quarters of 2019 and 2021 was 15%. And Jamie, as to kind of where we are. To choose Given the stronger recovery of procedures we have experienced so far, particularly in the U.S., and strength in U.S. general surgery, we are now increasing our forecast and expect full-year 2021 procedure growth of 27% to 30%. To choose Invest better with The Motley Fool. I think what we're seeing is that the longer diagnostic pipelines have had this kind of double effect from the pandemic. Intuitive has managed multiple ways of working for many years. Copyright 2023 Intuitive Surgical. And our posture to that has been -- it may delay some sales as we may have some competitive conversations and tenders, and we'll lose some. Intuitive Surgical, and Verb Surgical, among other countless innovations. The Company shipped 385 da Vinci Surgical Systems in the fourth quarter of 2021, compared with 326 systems in the fourth quarter of 2020. Intuitive will hold a teleconference at 1:30 p.m. PST today to discuss the fourth quarter 2021 financial results. Q4 2022 INTUITIVE Earnings Conference Call, INTUITIVE at J.P. Morgan Healthcare Conference, Q3 2022 INTUITIVE Earnings Conference Call, INTUITIVE at 2022 Wells Fargo Healthcare Conference, Q2 2022 INTUITIVE Earnings Conference Call, INTUITIVE at 43rd Annual Goldman Sachs Global Healthcare Conference, INTUITIVE at BofA Securities 2022 Healthcare Conference, Q1 2022 INTUITIVE Earnings Conference Call. And we're early in the Ion product cycle, and we're early in the SP or early mid in SP. China growth in the second quarter continued to be far higher than our other regions, primarily reflecting the 40% system installation growth over the past year. Intuitive Surgical's Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. Yes. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS and evaluating non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS together with net income attributable to Intuitive Surgical, Inc. and net income per share attributable to Intuitive Surgical, Inc. calculated in accordance with GAAP. My name is Kari Krogstad. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. I think all of us know, and we, as consumers know that customers like choice, perfectly fair. COVID-19 has had, and may continue to have, an adverse impact on the Companys procedure volumes. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., and non-GAAP EPS exclude items such as amortization of intangible assets, SBC and long-term incentive plan expenses, excess tax benefits or deficiencies associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfer of non-inventory assets, which are primarily recurring items. any time, re-enter your e-mail address and click Submit, then adjust your form entries. For full-year 2021, Intuitive Surgical revenues are estimated to be north of $5.7 billion, reflecting a 30% y-o-y growth, while the growth rate is expected to slow to low teens next year . We also -- the business came back faster than we had anticipated. For more information, please visit the Companys website at www.intuitive.com. Next, we will go to Amit Hazan with Goldman Sachs. The pandemic is not behind us, and additional infection growth may again strain hospital resources and impact our results in the future. Shifting to the extended use program, you know, you've been out for around six months, smaller rollout in Europe in the fourth quarter. Macroeconomic conditions created by COVID could regionally impact hospital capital spending. Our SEC filings can be found through our website or at the SEC's website. It's hard to have a precise measure on it. In terms of penetration or adoption, we're in the early to mid-innings kind of range is what I'd say in the U.S. market. May 2021 - Present 1 year 10 months. It's a short period, but we believe that there is elasticity, and we've seen elasticity in markets where reimbursements are very low. I'm here together with my CFO, Thomas Jakobsen.. | 2 Mrz 2023 . You're developing, trying to increase efficiency, decrease costs, that kind of thing. We expect our pro forma rate for the last six months of 2021 to be between 21% and 22% versus our previous guidance of 20% to 21%, reflecting a greater proportion of U.S. income for the year. Presentation: Operator. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.neuropace.com, on the Investors page in the News & Events section. We are building tools and capabilities that allow hospital departments and departments of surgery to manage their program and look across programmatics for efficiency, for learning, for outcomes, and these things interlink. Attendees can engage with peers, connect with Intuitive resource teams, and explore innovative robotic-assisted technology spanning the care continuum. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Growth Stocks to Buy Before the Big Bull Rally, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Copyright, Trademark and Patent Information. To change your e-mail options at Intuitive Surgical (ISRG-0.90%) investors who weren't expecting it to perform a three-for-one stock split recently woke up to what looked like an overnight loss of more than 60%. Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Beat Estimates . SUNNYVALE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2021.Reported revenue and procedure results are consistent with the Company's press release issued on January 12, 2022. That concludes our prepared comments. They're calling on customers. 3.5 Leading Players of Laparoscopy Surgical Robotic System and Consumables by Type in 2021 3.6 Conclusion of Segment by . Listen to Webcast. The Company ended the fourth quarter of 2022 with $6.74 billion in cash, cash equivalents, and investments, a decrease of $651 million during the quarter, primarily driven by share repurchases of $1 billion and capital expenditures, partially offset by cash generated from operations. Intuitive Announces Fourth Quarter Earnings, Intuitive Announces Preliminary Fourth Quarter and Full Year 2022 Results, Intuitive becomes largest robotic-assisted surgery provider to be accredited by the Royal College of Surgeons of England, Q4 2022 INTUITIVE Earnings Conference Call, INTUITIVE at J.P. Morgan Healthcare Conference, J.P. Morgan Healthcare Conference 2023 Presentation, Q3 2022 INTUITIVE Earnings Conference Call. Dec 2017 - Aug 20213 years 9 months. Intuitive Surgical Investor Presentation. Submit. ET. Listen to Webcast. There are no upcoming events available at this time. your options for e-mail notification, please enter your e-mail address below and click It's taking getting the advanced instruments, put them together as a set, getting our workflows and our clinical pathways right, and I think that's been powerful to date. That means that utilization will go up kind of naturally, that that mix moves toward a higher utilization mix. We have a broad range of estimates. Long-term incentive plan expense relates to phantom share awards granted in China by the Companys Intuitive-Fosun joint venture to its employees that vest over four years and can remain outstanding for seven to ten years. So first question for me is just trying to dissect your procedure results a little bit more because some really interesting comments, that you saw strength in benign cases, some catch-up cases. (4) Income tax expense includes the effect of the following items: One-time tax benefit from re-measurement of certain deferred tax assets, Discrete tax expense arising from the conclusion of a tax matter, Accounts payable and other accrued liabilities, Total liabilities and stockholders equity, Adjustments attributable to noncontrolling interest in joint venture. We believe value creation in surgery and acute care is foundationally human. The increase in cash in the second quarter primarily reflected cash from operations and stock exercises. And recently, we've had a series of very encouraging conversations on the adoption of bariatrics, very encouraging. A couple of things. In reporting the results, adjusted using a propensity weighted approach, the authors noted that during the two- to four-week standard of care visit period, fewer patients report the need to take prescription pain medication for the robotic cohort as compared to the laparoscopic and open cohorts: 65.2% for the robotic cohort as compared to 78.8% for the laparoscopic cohort, compared to 79.8% for the open cohort. We think there's an opportunity to look at correlations between surgeon performance and outcomes. any time, re-enter your e-mail address and click Submit, then adjust your form entries. Medistim ASA schlgt ordentliche Dividende fr 2021 vor, zahlbar am 9. And basically, still underpenetrated, big opportunity. Intuitive Surgical didn't offer an outlook for 2021. And I'd just be curious to -- since you all are calling it out repeatedly as an important incremental growth driver, where are we now, in your view, in that, I'm sure, multiyear, long-term adoption process? Intuitive develops, manufactures and markets the da Vinci surgical system. Mai 2022: CI. In Europe, the impact of COVID in the second quarter of 2021 varied regionally with slower recovery in Italy and France, while we saw early stages of a recovery in the U.K. Fourth quarter 2022 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $439 million, or $1.23 per diluted share, compared with $473 million, or $1.29 per diluted share, in the fourth quarter of 2021. Clinical Specialist - Chicago, IL Job in Chicago, IL at PROCEPT BioRobotics Listen to Webcast. Jamie Samath Senior Vice President Finance. The Company ended the fourth quarter of 2021 with $8.6 billion in cash, cash equivalents, and investments, an increase of $400million during the quarter, primarily driven by cash generated from operations. How are you thinking about competition? Copyright 2023 Intuitive Surgical. Investor's Business Daily . The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. With respect to operating expenses, on our last call, we forecast to grow full-year pro forma 2021 operating expenses between 18% and 22% above 2020 levels. We rolled out the extended use instruments in Europe and the U.S. back in the fourth quarter. There are several models of the da Vinci Surgical System. During the second half of 2022, the Company saw COVID-19 resurgences impact da Vinci procedure volumes in China. Our second-quarter 2021 performance was encouraging, with use of our systems for procedures growing beyond pre-pandemic levels and healthy capital placements. Intuitive Surgical Inc. (NASDAQ: ISRG) Q1 2021 earnings call dated Apr. And I have one follow-up. (2) Selling, general and administrative includes the effect of the following items: One-time tax benefit from re-measurement of certain deferred tax assets, Discrete tax expense arising from the conclusion of a tax matter, Gains on strategic investments, net of tax, Accounts payable and other accrued liabilities, Total liabilities and stockholders equity, Adjustments attributable to noncontrolling interest in joint venture. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Companys business. We continue to operate in a challenging supply chain environment and have experienced longer lead times and delayed deliveries from our suppliers. Intuitive Surgical, Inc. (ISRG) - Yahoo Finance And then has the elasticity relative to the extended use program and the pricing adjustments played out relative to your expectations? These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the risk that the COVID-19 pandemic could lead to further material delays and cancellations of, or reduced demand for, procedures; curtailed or delayed capital spending by hospitals; disruption to our supply chain, including increased difficulties in obtaining a sufficient amount of materials in the semiconductor and other markets; closures of our facilities; delays in surgeon training; delays in gathering clinical evidence; delays in obtaining new product approvals or clearances from the U.S. Food and Drug Administration (FDA) due to the effects of the COVID-19 pandemic; the evaluation of the risks of robotic-assisted surgery in the presence of infectious diseases; diversion of management and other resources to respond to the COVID-19 outbreaks; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 pandemic continues to disrupt local economies and causes economies in our key markets to enter prolonged recessions; the risk of our inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including our joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedures counts; regulatory approvals, clearances, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets in which we operate; risks associated with our operations outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party; product liability and other litigation claims; adverse publicity regarding us and the safety of our products and adequacy of training; our ability to expand into foreign markets; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risk factors. In the second quarter, we modified the useful life of a deferred-tax asset, which resulted in a current charge to pro forma income. I would just add, Bob, as you saw the COVID hospitalization rates in the U.S. come down in March and into Q2, that frees hospital resources to increase the level of surgery that we do. From a U.S. perspective, I think it's early, and I think we're simply acknowledging the risk. Tycho Peterson -- JPMorgan Chase & Co. -- Analyst. your options for e-mail notification, please enter your e-mail address below and click Second-quarter revenue reflected growth in both procedures and system placements. We're doing that as a combination of My Intuitive plus some of the simulation work that we do, plus some of the machine learning and video analysis work that we do. The next page will display a menu of options. Q2 2022 INTUITIVE Earnings Conference Call. I think that's what's been driving our success in the early market. 2022 Proxy Statement 36.4 MB. Just on the recent spread of COVID and variants and the potential impact on demand and hospitals' ability to do procedures, are you starting to see that impact now? And sequential growth in what they can do with the system remains our focus on SP for now. Turning to our innovation and commercialization efforts. The Company defines non-GAAP income from operations as income from operations, excluding intangible asset charges, certain acquisition-related items for the re-measurement of contingent consideration, SBC and long-term incentive plan expenses, and litigation charges and recoveries. The second reason to invest in Intuitive Surgical is its incredible profitability. Fourth-quarter revenue was in line with Intuitive Surgical's positive preannouncement earlier this month. And so we'll spend there. In addition to that, we still think this is a great opportunity to continue to invest in the ecosystem of products and capabilities at this point in time before competition really gets any kind of toehold. Intuitive Surgical Inc (ISRG) Q2 2021 Earnings Call Transcript And as competition progresses in various markets, we will likely experience longer selling cycles and price pressures. It's physically demanding. The Company's da Vinci Surgical System offers surgeons superior visualization, enhanced dexterity, greater precision and ergonomic comfort for the optimal performance of MIS. any time, re-enter your e-mail address and click Submit, then adjust your form entries. On our last call, we forecast our 2021 full-year pro forma gross profit margin to be within 70% and 71% of revenue. In Q2, U.S. procedures grew 77% year over year, which equates to 16% on a two-year compound annual growth rate basis. Intuitive 360 is an annual conference for executive, clinical, and operational leadership focusing on robotic service line development and the surgical care team. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Philip Kim, our head of investor relations, will not be joining on today's call as he's currently on paternity leave following the birth of his daughter. Submit. I think the product ecosystem with XI with a 60-millimeter stapler is in good shape, and we're getting good feedback from surgeons in that regard. The next page will display a menu of options. Non-GAAP gross profit. I think that would be a mistake. Next, we'll go to Bob Hopkins with Bank of America. These programs together trained over 2,200 care team members in the quarter, showing organizational strength and localizing programs, and responding with agility to pandemic-influenced demand. Our overall second-quarter procedure growth was 68%, compared to a decline of 19% during the second quarter of 2020, which reflected a significant adverse impact from the COVID-19 pandemic. This MMR report includes investor recommendations based on a thorough examination of the Thoracic Surgery Market's contemporary competitive scenario. Leasing represented 33% of current quarter placements, compared with 29% last year and 43% last quarter. Just a couple of comments. Jamie will discuss procedure and clinical highlights and provide an update of our financial outlook. We kind of outlined what was assumed in the high end of the procedure guidance. Our focus right now is not rapid expansion of the installed base. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our results of operations, growth strategy and commercial opportunity. The Company excludes a one-time tax benefit from re-measurement of certain deferred tax assets, because it is discrete in nature, and excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the on-going results of its core operations. Fourth quarter 2022 GAAP income from operations also included litigation charges of $21million. And those two things come together, they also allow hospitals to start to address the backlog that's accumulated. The Company ended the fourth quarter of 2022 with $6.74 billion in cash, cash equivalents, and investments, a decrease of $651 . I think we're going to have to let it play for another few quarters to see. Intuitive | ISRG Investor events & presentations - Intuitive Surgical We've seen a few teams come out and field systems that are alternatives to ours. Analysts: . We expect spending on activities restricted by COVID to increase as the impacts of the pandemic decline. And we've seen both good clinical outcomes, but also high surgeon satisfaction and better ergonomics. See www.intuitive.com/trademarks. Taken together, this combination of a recovery in procedures and healthy utilization supports our solid capital placement trends and rounds out a healthy commercial recovery year to date. The study contains 371 patients that underwent an incisional hernia repair procedure across 17 institutions within the United States between May 2016 and September 2019. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation (SBC) and long-term incentive plan expenses, and other special items. That will play out over the next several quarters as we accrue patients. The adjustments between pro forma and GAAP net income are outlined and quantified on our website. I will describe the highlights of our performance on a non-GAAP or pro forma basis. Lusi Chien - Chief Commercial Officer - Nanome Inc. | LinkedIn The high end of the range assumes strength in U.S. general surgery, a return to normalized diagnostic pipelines, the vaccines are effective against any new COVID-19 variants and the vaccine rollouts in OUS markets continue as currently expected by governments around the world. Where are we going with this one? The split must be approved by the shareholders but this is merely a formality. Jamie will take you through procedure dynamics in more detail later in the call. Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at https://isrg.gcs-web.com/. We anticipate iterating our approach as we learn and the year progresses. It's not just the robot. Having said that, it's a difficult procedure for surgeons to perform. Learn More, Intuitive Surgical(ISRG 2.61%)Q22021 Earnings CallJul 20, 2021, 4:30 p.m. Finally, we expect to continue to invest in expanding and accelerating our ecosystem of products and capabilities. Can you maybe just talk a little bit about the road map? In the quarter, we continued to engage customers in data analytics and opportunity analysis for surgical programs, cornerstone of our Your Data, Your Truth analytics efforts. To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (GAAP), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., non-GAAP net income per diluted share attributable to Intuitive Surgical, Inc. (EPS), and non-GAAP diluted shares outstanding. Customer appreciation and recurring use of our products has been growing nicely. Now, I'd turn the conference over to our host, Brian King, Head of Investor Relations for Intuitive Surgical. 2 Healthcare Stocks You Can Buy and Hold for the Next Decade, Why Things Could Get Worse Before They Get Better for This Growth Stock, 2 Stocks to Buy No Matter What Happens This Year, Why Intuitive Surgical Stock Slumped in January. Another third works closely with customers in the field, and the remaining third have traditionally worked in lab and office environments. And finally, we will host a question-and-answer session. Intuitive Surgical -Export management Iqm selezione - 07.2021 . At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. Field and marketing costs will tick up if the pandemic wanes. Intuitive Surgical Stock Is Getting Close To Fair Value Find the latest Intuitive Surgical, Inc. (ISRG) stock quote, history, news and other vital information to help you with your stock trading and investing. Non-GAAP gross profit. We also expect spending to increase as a percentage of revenue as investments in headcount, infrastructure, and other support areas catch up to the growth in the business. Listen to Webcast. And -- but right now, I think that remains to be seen how strong those other systems are. Copyright 2023 Intuitive Surgical. Intuitive Surgical (ISRG 0.58%) Q3 2021 Earnings Call Oct 19, 2021, 4:30 p.m. Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Intuitive Surgical Inc. (ISRG) Q4 2021 Earnings Call Transcript Pitching to investors 2023 | GIANT Health London 6th-7th December 2022 And as we've said in the past, if we can bring the right system with the right instruments, the right imaging, and the right usability, the right ease of use, we think that surgeons will care. We work closely and collaboratively . What we've seen, though, is that what happens in the PowerPoints and what happens a year later is different.
